Articles
Bad Pharma? Better laws needed

Bad Pharma? Better laws needed

Paul Gershlick addresses some of the points raised in Ben Goldacre’s book, Bad Pharma, and highlights what needs to change in order to achieve true transparency in the pharmaceutical industry. I have finished reading Ben Goldacre’s Bad Pharma book. I strongly recommend it. Whether you agree or disagree with…

Articles
AstraZeneca’s first direct-to-patient program – one year on

AstraZeneca’s first direct-to-patient program – one year on

Steven Davis, Executive Director, Foundation Brands, AstraZeneca shares his views on ARIMIDEX Direct – AstraZeneca’s first direct-to-patient program, and how successful its first year has been. A year ago, AstraZeneca announced its first direct-to-patient program in the US, whereby patients with a valid prescription could...

Articles
How much is that cure in the window? Pharma testing the waters of the cure

How much is that cure in the window? Pharma testing the wate...

Melissa Hogan, mother of a patient with a rare disease, explores the possibility of pharma developing cures for rare diseases. No one's ever asked me to run in a "Race for the Treatment." It certainly doesn't sound as motivating as a Race for the Cure…

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D